Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals (ARMP) Income towards Parent Company (2016 - 2018)

Historic Income towards Parent Company for Armata Pharmaceuticals (ARMP) over the last 6 years, with Q4 2018 value amounting to -$1.1 million.

  • Armata Pharmaceuticals' Income towards Parent Company rose 5318.88% to -$1.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$7.0 million, marking a year-over-year increase of 4565.32%. This contributed to the annual value of -$53.2 million for FY2024, which is 2270.81% down from last year.
  • Latest data reveals that Armata Pharmaceuticals reported Income towards Parent Company of -$1.1 million as of Q4 2018, which was up 5318.88% from -$2.8 million recorded in Q3 2018.
  • In the past 5 years, Armata Pharmaceuticals' Income towards Parent Company ranged from a high of -$779000.0 in Q3 2017 and a low of -$11.3 million during Q1 2014
  • Moreover, its 5-year median value for Income towards Parent Company was -$2.9 million (2015), whereas its average is -$3.9 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 69125.26% in 2014, then skyrocketed by 7661.1% in 2017.
  • Over the past 5 years, Armata Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$2.6 million in 2014, then dropped by 10.4% to -$2.9 million in 2015, then tumbled by 250.75% to -$10.1 million in 2016, then skyrocketed by 76.61% to -$2.4 million in 2017, then skyrocketed by 53.19% to -$1.1 million in 2018.
  • Its last three reported values are -$1.1 million in Q4 2018, -$2.8 million for Q3 2018, and -$3.2 million during Q2 2018.